Courses

A focus on modern systemic treatments for non-small cell lung cancer (NSCLC) as well as the gene faults that drive many NSCLCs; the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, and RET; the immune system and checkpoint inhibitor group of immunotherapies, including PD-1, PD-L1 and CTLA-4 targeted antibody therapies

The 4Ps Programme has been developed by research active healthcare professionals in Newcastle and is designed to support colleagues' needs no matter where they are on the “research interested” to “Aspiring Clinical Academic” continuum

During this introduction to the science behind a wide variety of systemic treatments given to people with prostate, bladder, or kidney cancer, Dr Elaine Vickers will discuss current hormone therapies, immunotherapy and targeted treatments.

This course explains why breast cancer arises, the different ways that the DNA in our cells gets damaged and the targeted treatments that match a few of the known mutations. It also explores the science behind hormone therapies, targeted therapies, and immunotherapies given to patients with hormone receptor-positive, HER2-positive, and triple-negative breast cancer.

This course provides an overview of the targeted therapies and immunotherapies given to some people with oesophageal, stomach, pancreatic or liver cancer, or cancers of the biliary system

The 4Ps Programme has been developed by research active healthcare professionals in Newcastle and is designed to support colleagues' needs no matter where they are on the “research interested” to “Aspiring Clinical Academic” continuum

This course describes how bowel cancer comes about, and explains the reasons why some patients might be given treatments such as EGFR-targeted antibodies (cetuximab and panitumumab), angiogenesis inhibitors (bevacizumab and regorafenib), or immune checkpoint inhibitors (pembrolizumab) as part of their treatment.

Knowledge gained through this course will enhance learners’ understanding of cancer biology, the mechanism of action of systemic cancer treatments, and the use of biomarkers to select the best treatments for each patient and as a result empower staff to feel confident when communicating with patients and their families, and with clinical and non-clinical colleagues.

The 4Ps Programme has been developed by research active Nurses, Midwives and Allied Health Professionals in Newcastle and is designed to support your needs no matter where you are on the “research interested” to “Aspiring Clinical Academic” continuum

The 4Ps Programme has been developed by research active Nurses, Midwives and Allied Health Professionals in Newcastle and is designed to support your needs no matter where you are on the “research interested” to “Aspiring Clinical Academic” continuum

This course gives cancer nurses and trial staff the knowledge and confidence to discuss a wide range of targeted cancer treatments and immunotherapies with patients and colleagues.

Ideal for research nurses, clinical nurse specialists, pharmacists, clinical trials and other staff who already have some knowledge of the different types of breast cancers. Delivered over two morning sessions, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through many of the most relevant topics relating to modern systemic treatments for breast cancer.